Clinical trial resumption - Increased R&D expenses were driven by resumed activities in the Phase 3 INVINCIBLE-3 sarcoma study.
Trial protocol modifications - Protocol amendments in the TNBC and sarcoma trials followed investigator feedback and regulatory review.
Preliminary trial data - Early results in the Phase 2 TNBC trial showed higher pathological complete response rates and fewer adverse events.
Analyst coverage
The current average analyst rating on the shares is buy, and the breakdown of recommendations is 5 strong buy or buy, no hold and no sell or strong sell.
Wall Street's median 12-month price target for Intensity Therapeutics Inc is $30.00, about 599.3% above its August 10 closing price of $4.29.
Trial updates and outlook
The company expects to resume U.S. enrollment in the INVINCIBLE-3 Phase 3 study by Q3 2026.
It targets complete enrollment in the INVINCIBLE-4 Phase 2 study by the end of 2027.
INTS•
